A cancer diagnosis rearranges everything, and for many patients, fertility is one of the first things pushed to the back burner while treatment takes priority. But once treatment ends, the question of whether IVF after cancer is still possible often becomes just as urgent as the diagnosis itself was. The good news: for many survivors, biological parenthood is still very much on the table — it just requires a protocol built around what chemotherapy, radiation, or surgery left behind, rather than a standard, one-size-fits-all approach.

The Fertility Landscape After Cancer Treatment

Cancer treatment can affect fertility in different ways depending on the type of cancer, the treatment protocol, the patient’s age at diagnosis, and how much time has passed since treatment ended. Some patients retain a healthy ovarian reserve. Others are left with diminished ovarian reserve (DOR), irregular cycles, or premature ovarian insufficiency (POI). None of these outcomes mean IVF is off the table — they simply mean the protocol needs to be individualised.

💡 Research suggests up to 70% of reproductive-age cancer survivors report fertility concerns after treatment, yet a large share never receive a formal fertility consultation before or after care begins.

This is precisely why oncofertility — the intersection of oncology and fertility care — has become its own specialty. Timing matters enormously. Patients who freeze eggs or embryos before chemotherapy begins generally have more options later. Patients who come to fertility care after treatment have already concluded still have paths forward, but the approach usually looks different: lower-dose stimulation, closer monitoring, and realistic expectations set from the very first appointment.

How Chemotherapy and Radiation Affect Ovarian Reserve

Chemotherapeutic agents, particularly alkylating agents like cyclophosphamide, are known to be gonadotoxic — they can accelerate the natural decline in the number of eggs a woman has in reserve. A 2024 study in Acta Endocrinologica found that alkylating chemotherapy is associated with a significantly higher risk of diminished ovarian reserve and earlier menopause compared with non-alkylating regimens, with the degree of impact closely tied to cumulative dose and the patient’s age at treatment.

Radiation to the pelvis carries similar risk, particularly when the ovaries fall within or near the treatment field. A 2026 study in Cynocologic Oncology Reports documented that even scatter radiation exposure can meaningfully reduce the primordial follicle pool, and that ovarian transposition — surgically repositioning the ovaries outside the radiation field before treatment — can help preserve function when performed in advance.

What this means clinically is that a survivor’s AMH (anti-Müllerian hormone) level and antral follicle count often tell a very different story than her age on paper. A 34-year-old survivor of alkylating chemotherapy may present with ovarian reserve markers more typical of a woman a decade older — which is exactly why complex-case fertility specialists build protocols around actual reserve, not chronological age.

San Diego’s Growing Oncofertility Community

San Diego is home to a dense concentration of academic medical centers, cancer treatment programs, and research institutions, which means a steady stream of patients moving between oncology teams and fertility specialists across the city. For survivors here, the logistics of coordinating cancer follow-up care with fertility treatment are often more straightforward than in smaller markets — records transfer between local providers relatively easily, and many oncologists in the area are accustomed to referring patients for fertility consultations either before or after treatment.

That said, coordination between oncology and fertility teams still requires a clinic that understands the nuances of post-treatment reproductive physiology, not just standard IVF protocols. Survivors deserve a team that reads their oncology history carefully before recommending a stimulation approach, rather than defaulting to whatever protocol works for the average patient walking through the door.

How Hanabusa IVF Adapts Protocols for Cancer Survivors

At Hanabusa IVF in San Diego, complex fertility cases are the specialty rather than the exception, and cancer survivors make up a meaningful share of the patients Dr. Lyndon Chang and Dr. Diana LeBlanc see for diminished ovarian reserve and premature ovarian insufficiency. The clinic’s approach starts from a simple premise: one size doesn’t fit all, and a survivor’s protocol should reflect what her ovaries can realistically do today, not what a standard stimulation calendar assumes.

That often means mini IVF or natural cycle IVF rather than high-dose conventional stimulation. Japanese-inspired, gentle stimulation protocols use lower medication doses aimed at retrieving fewer, higher-quality eggs rather than maximizing egg count — an approach that tends to suit survivors with reduced ovarian reserve particularly well, since aggressive stimulation on a depleted reserve often yields diminishing returns anyway.

For egg retrieval itself, Hanabusa IVF uses ultra-fine Japanese retrieval needles — 20-21 gauge, roughly half the thickness used at most IVF centers — and offers retrieval without IV sedation for patients who prefer it. For survivors who have already been through months or years of needles, infusions, and procedures, a gentler retrieval experience is not a minor detail; it matters.

The clinic is CAP accredited, AABB accredited, FDA registered, and reports to the CDC, and its 10+ years of vitrification expertise extends to a dedicated lab that also supports Asian Egg Bank, meaning survivors freezing eggs, embryos, or exploring donor egg options are working with a lab built around precision freezing and thawing outcomes, not a general-purpose facility.

Planning Ahead: Fertility Preservation Before Treatment Begins

For patients who haven’t yet started chemotherapy or radiation, the single most impactful decision is often made before treatment even begins: freezing eggs, embryos, or in some cases ovarian tissue while ovarian function is still at its baseline. Oncology teams increasingly build a fertility referral into the standard workflow for reproductive-age patients, but the timeline can be tight, sometimes just one to two weeks between diagnosis and the start of treatment, which is why a fast-moving, responsive fertility team matters as much as an experienced one.

A single round of egg or embryo freezing can typically be completed within about two weeks using an antagonist protocol, and in some cases stimulation can begin regardless of where a patient is in her menstrual cycle, avoiding the delay of waiting for a new cycle to begin naturally. For patients who can’t wait even that long, ovarian tissue cryopreservation, though less common, offers another option, particularly for prepubertal patients or those needing to start treatment immediately.

None of this diminishes the value of post-treatment fertility care for patients who weren’t able to preserve fertility beforehand, whether because treatment was urgent, the diagnosis came without warning, or fertility simply wasn’t front of mind at the time. Both paths deserve the same level of individualized attention, and both are conversations Hanabusa IVF has with patients every week.

The Emotional Side of Fertility After Cancer

Beyond the clinical picture, cancer survivors navigating fertility treatment are often carrying a layered emotional experience: relief at having completed treatment, anxiety about recurrence, and grief over reproductive possibilities that treatment may have taken away, all at once. A fertility team that has walked this path with other survivors tends to set expectations more honestly and compassionately, neither overpromising what a depleted ovarian reserve can deliver, nor closing doors that are still genuinely open.

Patients often find it helpful to have this conversation early, even before all diagnostic testing is complete, simply to understand the shape of the decisions ahead. Knowing the range of realistic options, from mini IVF with a survivor’s own eggs to donor egg programs if reserve turns out to be very limited, tends to reduce anxiety more than waiting for a single test result to arrive before discussing anything at all.

Frequently Asked Questions

Can I still do IVF if I’ve already finished cancer treatment?

Yes, in most cases. Ovarian reserve and hormone levels are checked first to understand where things stand, and the protocol is built from there, often a gentler, lower-stimulation approach if reserve has been affected.

How long after treatment should I wait before trying IVF?

This varies by cancer type and treatment, and is typically guided in coordination with your oncologist. Many patients begin fertility evaluation once their oncology team confirms it’s medically appropriate to proceed.

Does chemotherapy always cause infertility?

No. The impact depends on the specific drugs, cumulative dose, radiation exposure, and the patient’s age and baseline ovarian reserve. Some survivors retain normal fertility; others experience diminished reserve or premature ovarian insufficiency.

What if my ovarian reserve is very low after treatment?

Low reserve doesn’t rule out IVF, but it does change the approach. Mini IVF and natural cycle protocols are often better suited to a depleted reserve than aggressive stimulation, and donor egg options remain available if needed.

Do I need a referral from my oncologist?

A referral isn’t required, but coordination with your oncology team is strongly encouraged so your fertility team has full visibility into your treatment history and any current follow-up requirements.

You Don’t Have to Navigate This Alone

Whatever cancer treatment left behind, there is very likely a path forward, and it starts with an honest conversation about where things stand today.